In response to public comments and upon further review of evidence, Medicare Administrative Contractors (MACs) are not finalizing the most recently proposed Local Coverage Determination (LCD) for MolDx Molecular Testing for Solid Organ Allograft Rejection, which is a blood test that monitors for organ transplantation rejection, and instead anticipate issuing a new proposed LCD in the coming months. The Centers for Medicare and Medicaid Cervices (CMS) informed partners of this update.
Patients with transplanted hearts, lungs, or kidneys who meet Medicare’s existing local coverage criteria can continue to access these blood tests under the current LCD.
